5:39 PM
 | 
Sep 03, 2013
 |  BC Extra  |  Clinical News

Daiichi reports Phase III VTE data for edoxaban

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said once-daily edoxaban plus heparin met the primary efficacy endpoint of non-inferiority to warfarin plus heparin in the Phase III Hokusai-VTE trial to treat and prevent recurrence of acute symptomatic venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT) and/or...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >